Citations (59)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Catherine J. Y. Tsai, Jacelyn M. S. Loh, Kohtaro Fujihashi & Hiroshi Kiyono. (2023) Mucosal vaccination: onward and upward. Expert Review of Vaccines 22:1, pages 885-899.
Read now
Read now
Jingjing Zhang, Han Zhang & Litao Sun. (2022) Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?. mAbs 14:1.
Read now
Read now
Evalyne M Jansen, Henderik W Frijlink, Wouter LJ Hinrichs & Mitchel JR Ruigrok. (2022) Are inhaled mRNA vaccines safe and effective? A review of preclinical studies. Expert Opinion on Drug Delivery 19:11, pages 1471-1485.
Read now
Read now
Kaori Sano, Akira Ainai, Tadaki Suzuki & Hideki Hasegawa. (2018) Intranasal inactivated influenza vaccines for the prevention of seasonal influenza epidemics. Expert Review of Vaccines 17:8, pages 687-696.
Read now
Read now
Yoshihiko Terauchi, Kaori Sano, Akira Ainai, Shinji Saito, Yuki Taga, Kiyoko Ogawa-Goto, Shin-ichi Tamura, Takato Odagiri, Masato Tashiro, Mikiya Fujieda, Tadaki Suzuki & Hideki Hasegawa. (2018) IgA polymerization contributes to efficient virus neutralization on human upper respiratory mucosa after intranasal inactivated influenza vaccine administration. Human Vaccines & Immunotherapeutics 14:6, pages 1351-1361.
Read now
Read now
Cécile van Els, Siri Mjaaland, Lisbeth Næss, Julia Sarkadi, Eva Gonczol, Karen Smith Korsholm, Jon Hansen, Jørgen de Jonge, Gideon Kersten, Jennifer Warner, Amanda Semper, Corine Kruiswijk & Fredrik Oftung. (2014) Fast vaccine design and development based on correlates of protection (COPs): Influenza as a trendsetter. Human Vaccines & Immunotherapeutics 10:7, pages 1935-1948.
Read now
Read now
Articles from other publishers (53)
Kana Shiraishi, Osamu Yoshida, Yusuke Imai, Sheikh Akbar, Takahiro Sanada, Michinori Kohara, Takashi Miyazaki, Taizou Kamishita, Teruki Miyake, Masashi Hirooka, Yoshio Tokumoto, Masanori Abe, Julio Rubido, Gerardo Nieto & Yoichi Hiasa. (2023) Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders. Vaccines 11:9, pages 1479.
Crossref
Crossref
Chandramani Singh, Savita Verma, Prabhakar Reddy, Michael S. Diamond, David T. Curiel, Chintan Patel, Manish Kumar Jain, Sagar Vivek Redkar, Amit Suresh Bhate, Vivek Gundappa, Rambabu Konatham, Leelabati Toppo, Aniket Chandrakant Joshi, Jitendra Singh Kushwaha, Ajit Pratap Singh, Shilpa Bawankule, Raches Ella, Sai Prasad, Brunda Ganneru, Siddharth Reddy Chiteti, Sreenivas Kataram & Krishna Mohan Vadrevu. (2023) Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®). npj Vaccines 8:1.
Crossref
Crossref
Matt D T Hitchings, Brooke A Borgert, Adam Shir, Bingyi Yang, Kyra H Grantz, Jacob Ball, Carlos A Moreno, Kenneth Rand, Parker A SmallJrJr, Keith R Fowke & Derek A T Cummings. (2023) Dynamics of Anti-influenza Mucosal IgA Over a Season in a Cohort of Individuals Living or Working in a Long-term Care Facility. The Journal of Infectious Diseases 228:4, pages 383-390.
Crossref
Crossref
Yoshihito Nihei, Mizuki Higashiyama, Kosuke Miyauchi, Kei Haniuda, Yusuke Suzuki, Masato Kubo & Daisuke Kitamura. (2023) Subcutaneous immunisation with zymosan generates mucosal IgA-eliciting memory and protects mice from heterologous influenza virus infection. International Immunology 35:8, pages 377-386.
Crossref
Crossref
Teeraporn C. Bureerug, Sitthichai Kanokudom, Nungruthai Suntronwong, Ritthideach Yorsaeng, Suvichada Assawakosri, Thanunrat Thongmee & Yong Poovorawan. (2023) Evaluation of Anti-S1 IgA Response to Different COVID-19 Vaccination Regimens. Vaccines 11:6, pages 1117.
Crossref
Crossref
Ayae Nishiyama, Yu Adachi, Keisuke Tonouchi, Saya Moriyama, Lin Sun, Masamitsu Aoki, Hideki Asanuma, Masayuki Shirakura, Akihisa Fukushima, Takuya Yamamoto & Yoshimasa Takahashi. (2023) Post-fusion influenza vaccine adjuvanted with SA-2 confers heterologous protection via Th1-polarized, non-neutralizing antibody responses. Vaccine.
Crossref
Crossref
Jun Liu, Xiao-Dan Yan, Xian-Qiang Li, Yu-Hao Du, Li-Li Zhu, Tian-Tian Ye, Ze-Ying Cao, Zhe-Wen Dong, Shu-Tao Li, Xue Xu, Wei Bai, Dan Li, Ji-Wen Zhang, Shu-Jun Wang, Shan-Hu Li, Jin Sun & Xian-Zhen Yin. (2023) Chrysanthemum sporopollenin: A novel vaccine delivery system for nasal mucosal immunity. Frontiers in Immunology 14.
Crossref
Crossref
Jenny Lorena Molina Estupiñan, Audur Anna Aradottir Pind, Poorya Foroutan Pajoohian, Ingileif Jonsdottir & Stefania P. Bjarnarson. (2023) The adjuvants dmLT and mmCT enhance humoral immune responses to a pneumococcal conjugate vaccine after both parenteral or mucosal immunization of neonatal mice. Frontiers in Immunology 13.
Crossref
Crossref
John Joseph. (2022) Harnessing Nasal Immunity with IgA to Prevent Respiratory Infections. Immuno 2:4, pages 571-583.
Crossref
Crossref
Fumi Sato-Kaneko, Shiyin Yao, Fitzgerald S. Lao, Yukiya Sako, Jasmine Jin, Nikunj M. Shukla, Howard B. Cottam, Michael Chan, Masiel M. Belsuzarri, Dennis A. Carson & Tomoko Hayashi. (2022) A Dual Adjuvant System for Intranasal Boosting of Local and Systemic Immunity for Influenza Vaccination. Vaccines 10:10, pages 1694.
Crossref
Crossref
Xuan Lin, Yanan Sheng, Xuan Zhang, Zhengjun Li, Yanli Yang, Jie Wu, Zhiguo Su, Guanghui Ma & Songping Zhang. (2022) Oil-in-ionic liquid nanoemulsion-based intranasal delivery system for influenza split-virus vaccine. Journal of Controlled Release 346, pages 380-391.
Crossref
Crossref
Ed C. Lavelle & Ross W. Ward. (2021) Mucosal vaccines — fortifying the frontiers. Nature Reviews Immunology 22:4, pages 236-250.
Crossref
Crossref
Yasuko Tsunetsugu-Yokota, Sayaka Ito, Yu Adachi, Taishi Onodera, Tsutomu Kageyama & Yoshimasa Takahashi. (2022) Saliva as a useful tool for evaluating upper mucosal antibody response to influenza. PLOS ONE 17:2, pages e0263419.
Crossref
Crossref
Chisa Fujimoto & Noriaki Takeda. (2022) Defensive Role of Viral-Specific Nasal Secretory IgA Antibody Against Influenza Infection in Adults: Translational Research in the Development of Intranasal Vaccinesインフルエンザ感染防御におけるウイルス特異的鼻腔分泌型IgA抗体の役割. Practica oto-rhino-laryngologica. Suppl. 158:0, pages 110-118.
Crossref
Crossref
Dennis Lapuente, Jana Fuchs, Jonas Willar, Ana Vieira Antão, Valentina Eberlein, Nadja Uhlig, Leila Issmail, Anna Schmidt, Friederike Oltmanns, Antonia Sophia Peter, Sandra Mueller-Schmucker, Pascal Irrgang, Kirsten Fraedrich, Andrea Cara, Markus Hoffmann, Stefan Pöhlmann, Armin Ensser, Cordula Pertl, Torsten Willert, Christian Thirion, Thomas Grunwald, Klaus Überla & Matthias Tenbusch. (2021) Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. Nature Communications 12:1.
Crossref
Crossref
Haiyue Xu, Lucy Cai, Stephanie Hufnagel & Zhengrong Cui. (2021) Intranasal vaccine: Factors to consider in research and development. International Journal of Pharmaceutics 609, pages 121180.
Crossref
Crossref
Krystal T. Hamorsky, Adrienne M. Bushau-Sprinkle, Kathleen Kitterman, Julia M. Corman, Jennifer DeMarco, Rachel J. Keith, Aruni Bhatnagar, Joshua L. Fuqua, Amanda Lasnik, Joongho Joh, Donghoon Chung, Jon Klein, Joseph Flynn, Marti Gardner, Shirish Barve, Smita S. Ghare & Kenneth E. Palmer. (2021) Serological assessment of SARS-CoV-2 infection during the first wave of the pandemic in Louisville Kentucky. Scientific Reports 11:1.
Crossref
Crossref
Jun-Gyu Park, Fatai S. Oladunni, Mohammed A. Rohaim, Jayde Whittingham-Dowd, James Tollitt, Matthew D.J. Hodges, Nadin Fathallah, Muhsref Bakri Assas, Wafaa Alhazmi, Abdullah Almilaibary, Munir Iqbal, Pengxiang Chang, Renee Escalona, Vinay Shivanna, Jordi B. Torrelles, John J. Worthington, Lucy H. Jackson-Jones, Luis Martinez-Sobrido & Muhammad Munir. (2021) Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2. iScience 24:9, pages 102941.
Crossref
Crossref
Osamu Kotani, Yasushi Suzuki, Shinji Saito, Akira Ainai, Akira Ueno, Takuya Hemmi, Kaori Sano, Koshiro Tabata, Masaru Yokoyama, Tadaki Suzuki, Hideki Hasegawa & Hironori Sato. (2021) Structure-Guided Creation of an Anti-HA Stalk Antibody F11 Derivative That Neutralizes Both F11-Sensitive and -Resistant Influenza A(H1N1)pdm09 Viruses. Viruses 13:9, pages 1733.
Crossref
Crossref
Meito Shibuya, Shigeyuki Tamiya, Atsushi Kawai & Yasuo Yoshioka. (2021) Nasal–subcutaneous prime–boost regimen for inactivated whole-virus influenza vaccine efficiently protects mice against both upper and lower respiratory tract infections. Biochemical and Biophysical Research Communications 554, pages 166-172.
Crossref
Crossref
Harshad P. PatilPrajakta S. RaneShubham ShrivastavaSonali PalkarSanjay LalwaniAkhilesh C. MishraVidya A. Arankalle. (2021) Antibody (IgA, IgG, and IgG Subtype) Responses to SARS-CoV-2 in Severe and Nonsevere COVID-19 Patients. Viral Immunology 34:3, pages 201-209.
Crossref
Crossref
Delphine Sterlin, Alexis Mathian, Makoto Miyara, Audrey Mohr, François Anna, Laetitia Claër, Paul QuentricJehane Fadlallah, Hervé Devilliers, Pascale Ghillani, Cary Gunn, Rick Hockett, Sasi Mudumba, Amélie GuihotCharles-Edouard Luyt, Julien Mayaux, Alexandra Beurton, Salma Fourati, Timothée Bruel, Olivier Schwartz, Jean-Marc Lacorte, Hans Yssel, Christophe Parizot, Karim Dorgham, Pierre Charneau, Zahir Amoura & Guy Gorochov. (2021) IgA dominates the early neutralizing antibody response to SARS-CoV-2. Science Translational Medicine 13:577.
Crossref
Crossref
Kaori Sano, Shinji Saito, Tadaki Suzuki, Osamu Kotani, Akira Ainai, Elly van Riet, Koshiro Tabata, Kumpei Saito, Yoshimasa Takahashi, Masaru Yokoyama, Hironori Sato, Takahiro Maruno, Kaede Usami, Susumu Uchiyama, Kiyoko Ogawa-Goto & Hideki Hasegawa. (2021) An influenza HA stalk reactive polymeric IgA antibody exhibits anti-viral function regulated by binary interaction between HA and the antibody. PLOS ONE 16:1, pages e0245244.
Crossref
Crossref
Delphine Sterlin & Guy Gorochov. (2021) When Therapeutic IgA Antibodies Might Come of Age. Pharmacology 106:1-2, pages 9-19.
Crossref
Crossref
Indu Khatri, Frank J. T. Staal & Jacques J. M. van Dongen. (2020) Blocking of the High-Affinity Interaction-Synapse Between SARS-CoV-2 Spike and Human ACE2 Proteins Likely Requires Multiple High-Affinity Antibodies: An Immune Perspective. Frontiers in Immunology 11.
Crossref
Crossref
Pankoj Kumar Das & Irene Salinas. (2020) Fish nasal immunity: From mucosal vaccines to neuroimmunology. Fish & Shellfish Immunology 104, pages 165-171.
Crossref
Crossref
Mrityunjoy Biswas, Tatsuya Yamazaki, Joe Chiba & Sachiko Akashi-Takamura. (2020) Broadly Neutralizing Antibodies for Influenza: Passive Immunotherapy and Intranasal Vaccination. Vaccines 8:3, pages 424.
Crossref
Crossref
Akira Ainai, Elly Riet, Ryo Ito, Kazuyuki Ikeda, Kyosuke Senchi, Tadaki Suzuki, Shin‐ichi Tamura, Hideki Asanuma, Takato Odagiri, Masato Tashiro, Takeshi Kurata, Pretty Multihartina, Vivi Setiawaty, Krisna Nur Andriana Pangesti & Hideki Hasegawa. (2020) Human immune responses elicited by an intranasal inactivated H5 influenza vaccine. Microbiology and Immunology 64:4, pages 313-325.
Crossref
Crossref
Olivia A. Vogel & Balaji Manicassamy. (2020) Broadly Protective Strategies Against Influenza Viruses: Universal Vaccines and Therapeutics. Frontiers in Microbiology 11.
Crossref
Crossref
Alessandro Manenti, Agnieszka Katarzyna Maciola, Claudia Maria Trombetta, Otfried Kistner, Elisa Casa, Inesa Hyseni, Ilaria Razzano, Alessandro Torelli & Emanuele Montomoli. (2020) Influenza Anti-Stalk Antibodies: Development of a New Method for the Evaluation of the Immune Responses to Universal Vaccine. Vaccines 8:1, pages 43.
Crossref
Crossref
Hideki Hasegawa. 2020. Mucosal Vaccines. Mucosal Vaccines
677
682
.
Joon Haeng Rhee. 2020. Mucosal Vaccines. Mucosal Vaccines
325
356
.
Takahiro Sanada, Naoki Yamamoto, Mohammad Enamul Hoque Kayesh, Kyoko Tsukiyama-Kohara, Hideki Hasegawa, Takashi Miyazaki, Jun-ichiro Takano, Yumiko Shiogama, Yasuhiro Yasutomi, Yasumasa Goh, Osamu Yoshida, Yoichi Hiasa & Michinori Kohara. (2019) Intranasal vaccination with HBs and HBc protein combined with carboxyl vinyl polymer induces strong neutralizing antibody, anti-HBs IgA, and IFNG response. Biochemical and Biophysical Research Communications 520:1, pages 86-92.
Crossref
Crossref
Elena Gianchecchi, Alessandro Manenti, Otfried Kistner, Claudia Trombetta, Ilaria Manini & Emanuele Montomoli. (2019) How to assess the effectiveness of nasal influenza vaccines? Role and measurement of sIgA in mucosal secretions. Influenza and Other Respiratory Viruses 13:5, pages 429-437.
Crossref
Crossref
Shinji Saito, Kaori Sano, Tadaki Suzuki, Akira Ainai, Yuki Taga, Tomonori Ueno, Koshiro Tabata, Kumpei Saito, Yuji Wada, Yuki Ohara, Haruko Takeyama, Takato Odagiri, Tsutomu Kageyama, Kiyoko Ogawa-Goto, Pretty Multihartina, Vivi Setiawaty, Krisna Nur Andriana Pangesti & Hideki Hasegawa. (2019) IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody. PLOS Pathogens 15:1, pages e1007427.
Crossref
Crossref
Tadaki SUZUKI & Hideki HASEGAWA. (2019) IgA antibodies contribute to protection against influenza virus infectionIgA抗体によるインフルエンザウイルス感染防御. Uirusu 69:2, pages 153-160.
Crossref
Crossref
Katsuiku Hirokawa & Masanori Utsuyama. 2019. Handbook of Immunosenescence. Handbook of Immunosenescence
2767
2793
.
Xiaoyong Chen, Shasha Liu, Mohsan Ullah Goraya, Mohamed Maarouf, Shile Huang & Ji-Long Chen. (2018) Host Immune Response to Influenza A Virus Infection. Frontiers in Immunology 9.
Crossref
Crossref
Katsuiku Hirokawa & Masanori Utsuyama. 2018. Handbook of Immunosenescence. Handbook of Immunosenescence
1
27
.
Kaori Sano, Akira Ainai, Tadaki Suzuki & Hideki Hasegawa. (2017) The road to a more effective influenza vaccine: Up to date studies and future prospects. Vaccine 35:40, pages 5388-5395.
Crossref
Crossref
Tadaki Suzuki, Akira Ainai & Hideki Hasegawa. (2017) Functional and structural characteristics of secretory IgA antibodies elicited by mucosal vaccines against influenza virus. Vaccine 35:39, pages 5297-5302.
Crossref
Crossref
Akira AinaiTadaki SuzukiShin-ichi TamuraHideki Hasegawa. (2017) Intranasal Administration of Whole Inactivated Influenza Virus Vaccine as a Promising Influenza Vaccine Candidate. Viral Immunology 30:6, pages 451-462.
Crossref
Crossref
Misako Nakayama, Yasushi Itoh, Shintaro Shichinohe, Rumi Nakabayashi, Hirohito Ishigaki, Yoshihiro Sakoda, Quynh Mai Le, Yoshihiro Kawaoka, Hiroshi Kida & Kazumasa Ogasawara. (2017) Potential risk of repeated nasal vaccination that induces allergic reaction with mucosal IgE and airway eosinophilic infiltration in cynomolgus macaques infected with H5N1 highly pathogenic avian influenza virus. Vaccine 35:7, pages 1008-1017.
Crossref
Crossref
Shu-Ting Ren, Xue-Mei Zhang, Peng-Fei Sun, Li-Juan Sun, Xue Guo, Tian Tian, Jian Zhang, Qi-Yuan Guo, Xue Li, Li-Jun Guo, Jin Che, Bing Wang & Hui Zhang. (2017) Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59. PLOS ONE 12:1, pages e0169501.
Crossref
Crossref
Daniel F. Hoft, Kathleen R. Lottenbach, Azra Blazevic, Aldin Turan, Tamara P. Blevins, Thomas P. Pacatte, Yinyi Yu, Michelle C. Mitchell, Stella G. Hoft & Robert B. Belshe. (2017) Comparisons of the Humoral and Cellular Immune Responses Induced by Live Attenuated Influenza Vaccine and Inactivated Influenza Vaccine in Adults. Clinical and Vaccine Immunology 24:1.
Crossref
Crossref
Philip J. Bergin, Robert Langat, Gloria Omosa-Manyonyi, Bashir Farah, Gina Ouattara, Harriet Park, Helen Coutinho, Dagna Laufer, Pat Fast, Carl Verlinde, Jean Bizimana, Gisele Umviligihozo, Julien Nyombayire, Rosine Ingabire, Kristin Kuldanek, Josephine Cox, Martin McMorrow, Sarah Fidler, Etienne Karita, Jill Gilmour & Omu Anzala. (2016) Assessment of Anti–HIV-1 Antibodies in Oral and Nasal Compartments of Volunteers From 3 Different Populations. JAIDS Journal of Acquired Immune Deficiency Syndromes 73:2, pages 130-137.
Crossref
Crossref
Shinji Saito, Akira Ainai, Tadaki Suzuki, Norihiro Harada, Yasushi Ami, Yoshikazu Yuki, Haruko Takeyama, Hiroshi Kiyono, Hideo Tsukada & Hideki Hasegawa. (2016) The effect of mucoadhesive excipient on the nasal retention time of and the antibody responses induced by an intranasal influenza vaccine. Vaccine 34:9, pages 1201-1207.
Crossref
Crossref
Akira AWAYA. (2016) Suppressive influence of seasonal influenza epidemic on Kawasaki disease onset. Japanese Journal of Clinical Immunology 39:6, pages 528-537.
Crossref
Crossref
Shirene M. Singh, Tamiru N. Alkie, Douglas C. Hodgins, Éva Nagy, Bahram Shojadoost & Shayan Sharif. (2015) Systemic immune responses to an inactivated, whole H9N2 avian influenza virus vaccine using class B CpG oligonucleotides in chickens. Vaccine 33:32, pages 3947-3952.
Crossref
Crossref
Tadaki SuzukiAkira KawaguchiAkira AinaiShin-ichi TamuraRyo ItoPretty Multihartina, Vivi Setiawaty, Krisna Nur Andriana Pangesti, Takato OdagiriMasato TashiroHideki Hasegawa. (2015) Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus. Proceedings of the National Academy of Sciences 112:25, pages 7809-7814.
Crossref
Crossref
Trinh Vo, Rikhav Gala, Thripthy Chandran, Sucheta D'Sa & Ruhi Ubale. 2015. Nanoparticulate Vaccine Delivery Systems. Nanoparticulate Vaccine Delivery Systems
15
59
.
Tatsuhiko Azegami, Yoshikazu Yuki & Hiroshi Kiyono. (2014) Challenges in mucosal vaccines for the control of infectious diseases. International Immunology 26:9, pages 517-528.
Crossref
Crossref
Hideki Hasegawa, Elly van Reit & Hiroshi Kida. 2015. Influenza Pathogenesis and Control - Volume II. Influenza Pathogenesis and Control - Volume II
371
380
.